Regresar

Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial

Abstract:

BACKGROUND: The prognosis of patients bearing high grade glioma remains dismal. Epidermal Growth Factor Receptor (EGFR) is well validated as a primary contributor of glioma initiation and progression. Nimotuzumab is a humanized monoclonal antibody that recognizes the EGFR extracellular domain and reaches Central Nervous System tumors, in nonclinical and clinical setting. While it has similar activity when compared to other anti-EGFR antibodies, it does not induce skin toxicity or hypomagnesemia.

Año de publicación:

2013

Keywords:

    Fuente:

    scopusscopus

    Tipo de documento:

    Article

    Estado:

    Acceso abierto

    Áreas de conocimiento:

    • Cáncer
    • Medicamento

    Áreas temáticas:

    • Farmacología y terapéutica
    • Enfermedades
    • Medicina y salud

    Contribuidores:

    Figueredo J.Figueredo J.
    Ballesteros J.Ballesteros J.
    Alert J.Alert J.
    Bach F.Bach F.
    de-Castro N.de-Castro N.
    Salva S.Salva S.
    Tania CrombetTania Crombet
    Luaces P.L.o.Luaces P.L.o.
    Quintanal N.Quintanal N.
    Marinello J.J.u.Marinello J.J.u.
    Toledo C.Toledo C.
    Catala M.Catala M.
    Martell J.A.n.Martell J.A.n.
    Selva J.C.é.Selva J.C.é.
    Solomón M.T.e.Solomón M.T.e.
    Griego M.G.o.Griego M.G.o.
    Vaquer J.Vaquer J.
    Domíngez R.Domíngez R.